Alzheimer’s Disease Therapeutics & Diagnostics Market Analysis

From Amyloid to Tau: Solutions to Alzheimer’s Disease Management

The Alzheimer’s disease therapeutics & diagnostics sphere is experiencing heightened urgency as cases continue to rise globally. In 2020, more than 55 million people worldwide were affected by dementia. This figure is projected to grow to 78 million by 2030 and 139 million by 2050. The increasing prevalence emphasizes the critical need for advanced diagnostics and innovative therapeutics to manage this condition.

In this regard, Biogen Inc is at the forefront of efforts to address Alzheimer’s disease. In collaboration with Eisai, Biogen is advancing LEQEMBI® (lecanemab-irmb), the first FDA-approved anti-amyloid beta treatment with traditional approval in the United States. By expediting LEQEMBI’s global launch, Biogen aims to tackle amyloid-beta pathology, a key factor in the progression of Alzheimer’s disease.

In addition to LEQEMBI, Biogen is extending its pipeline to address other core pathologies of Alzheimer’s:

• BIIB080, an antisense oligonucleotide, is designed to reduce tau protein accumulation, a major contributor to neurodegeneration.
• BIIB113, an oral small molecule inhibitor, is under development to prevent tau aggregation, targeting another critical driver of the disease.

Other companies are also contributing to the growing domain of Alzheimer’s treatments:

• Eli Lilly’s drug candidate, donanemab, has shown promising results in clinical trials, reducing the risk of disease progression by 39%. It also slowed the decline in daily activities by 40% and prevented disease worsening in 47% of participants, as measured by CDR-SB.
  

• Novo Nordisk is conducting clinical trials to explore the potential of semaglutide as a treatment for Alzheimer’s disease.
  

• AriBio Co Ltd is developing AR1001, a disease-modifying small molecule aimed at halting disease progression.
  

• Otsuka Pharmaceutical Development & Commercialization Inc is advancing AVP-786, a neuropsychiatric symptom agent designed to manage behavioral and psychological symptoms in Alzheimer’s patients.

These advancements represent a holistic approach to Alzheimer’s disease therapeutics & diagnostics, targeting both amyloid-beta plaques and tau tangles. As the global prevalence of Alzheimer’s continues to grow, ongoing innovations in this field are essential to addressing the rising challenge and enhancing outcomes for patients globally.

Stay up-to-date with what’s trending in the Global Alzheimer’s Disease Therapeutics & Diagnostics Market

Alzheimer’s Disease Therapeutics & Diagnostics Market: Early Detection & AI Innovations

The Alzheimer’s disease therapeutics & diagnostics market is progressing swiftly, boosted by advancements in brain imaging technologies and the integration of artificial intelligence (AI). While traditional imaging techniques like MRI scans are vital for detecting markers such as amyloid plaques and tau tangles, AI enhances diagnostic capabilities. Additionally, recent innovations in the field are improving diagnostic accuracy, offering new possibilities for personalized treatment and enabling earlier, more effective interventions.

In essence, researchers at the Keck School of Medicine and USC Viterbi School of Engineering are leading efforts to apply AI in advancing Alzheimer’s diagnostics. The AI algorithms, trained on extensive datasets, including MRI scans, genomic data, and traditional biomarkers, have achieved over 90% accuracy in diagnosing Alzheimer’s. This development is important for early detection, as it plays a key role in effective disease management and treatment. (Source)

Further advancing these efforts, GE HealthCare’s MIM Software recently received FDA clearance for Centiloid scaling in PET-based amyloid imaging. Integrated into the MIMneuro platform, this tool standardizes the quantification of amyloid plaques, enhancing diagnostic precision and clinician confidence. PET imaging, combined with tools like Centiloid scaling, strengthens Alzheimer’s care pathways by enabling early detection, supporting personalized treatment plans, and advancing therapeutic research. (Source)

Hence, these evolutions in brain imaging are transforming Alzheimer’s care by improving early diagnosis, personalizing treatment approaches, and accelerating therapeutic development.

Market Position: As per Inkwood Research, in 2023, brain imaging was the major diagnostics in the global Alzheimer’s disease therapeutics & diagnostics market. 

Kindly click here to view the LinkedIn post related to this market

Alzheimer’s Disease Therapeutics & Diagnostics Market: Addressing Global Aging Epidemic

The Alzheimer’s disease therapeutics & diagnostics market is developing with the expansion of the elderly population. As the global population ages, the number of individuals affected by Alzheimer’s is projected to increase. The prevalence of Alzheimer’s rises with age—while only 5% of people aged 65 to 74 are affected, this figure reaches 33.3% among those aged 85 and older.

In this regard, countries like China, India, and neighboring regions are experiencing some of the fastest growth in their elderly populations. In India, for example, the population over 60 is projected to comprise 19.1% of the total population by 2050. This demographic shift is expected to contribute to a higher incidence of Alzheimer’s, further increasing the demand for effective diagnostic tools and therapeutic solutions. (Source)

• As per Inkwood Research, the India Alzheimer’s disease therapeutics & diagnostics market is anticipated to prosper at a CAGR of 6.40% over the forecast period. 

Moreover, in 2023, the estimated cost of healthcare, long-term care, and hospice services for US individuals aged 65 and older with dementia reached $345 billion, emphasizing the financial burden of Alzheimer’s. 

• According to Inkwood Research, the United States Alzheimer’s disease therapeutics & diagnostics market is predicted to develop at a CAGR of 5.75% over the forecast period. 

Thus, as the elderly population continues to surge, addressing these healthcare challenges propels advancements in Alzheimer’s disease therapeutics & diagnostics globally. 

As the global prevalence of Alzheimer’s disease continues to escalate, the Alzheimer’s disease therapeutics & diagnostics market is witnessing substantial growth. Progressions in brain imaging technologies are playing a pivotal role in early detection, improving diagnostic accuracy, and enabling better management of the disease. 

Furthermore, the growing elderly population is driving the demand for more precise diagnostic tools and therapies as the risk of Alzheimer’s increases with age. With these ongoing developments, the Alzheimer’s disease therapeutics & diagnostics market is expected to grow during the forecast period.

Explore the market insights in this YouTube video by clicking here

By Harshita Kumari